Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

Exclusion Criteria

• •1. Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
• •2. Previous recipient of a liver transplant
• •3. Co-infection with human immunodeficiency virus (HIV) or hepatitis C (HCV) or hepatitis D (HDV)
• •4. Severe or uncontrolled comorbidities
• •5. Current or known hepatic decompensation (≤2 years) (e.g ascites, encephalopathy, or variceal hemorrhage) with a Child-Pugh score of B or C
• •6. Malignancy including liver cancer within 5 years except cancers curable by surgical resection (e.g. basal cell skin cancer and squamous cell cancer)
• •7. On any of the disallowed concomitant medications listed in the prior and concomitant medications list (pg. 11). Subjects on prohibited medications who are otherwise eligible will need a wash out period of at least 30 days prior to the Screening/Baseline visit.
• •8. Males and females of reproductive potential who are unwilling to use "effective" protocol-specified method(s) of contraception during the study.
• •9. Current substance or alcohol abuse judged by the investigator to potentially interfere with subject compliance.
• •10. Any other clinical conditions that, in the opinion of the Investigator, would make the subject unsuitable or unable to comply with any of the study procedures